PositoAI/ US/ Tyra Biosciences, Inc.

Tyra Biosciences, Inc.

NasdaqGS: TYRA · Healthcare

Positivity Index

#4,427 / 6,774

Global

#2,208 / 4,000

United States

Positivity Score

19,477

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Tyra Biosciences, Inc. — Overview & Financial Snapshot

Tyra Biosciences, Inc. (NasdaqGS: TYRA) is a Healthcare company, ranked #4,427 of 6,774 companies globally and #2,208 of 4,000 in United States on PositoAI, with a Positivity Score of 19,477. Its market capitalisation is ₹13,544.48 Cr ($1.43B), P/E ratio is -8.7 and P/B ratio is 4.06. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

P/B Ratio 4.06

P/E Ratio -8.7

D/E Ratio 0.02

ROE -45.31%

Owes vs Owns ? 0.08× Low $0.08 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-225.59$-2.39

Forward EPS ₹-261.52$-2.77

Beta 0.75

Market Cap ₹13,544.48 Cr$1.43B

What these numbers mean →

What does Tyra Biosciences, Inc. do?

What is Tyra Biosciences, Inc.'s P/E and P/B ratio?

Tyra Biosciences, Inc. has a P/E ratio of -8.7 and a P/B ratio of 4.06.

What is Tyra Biosciences, Inc.'s debt-to-equity ratio?

Tyra Biosciences, Inc. has a debt-to-equity ratio of 0.02.

How much does Tyra Biosciences, Inc. owe compared with what it owns?

Tyra Biosciences, Inc. owes $0.08 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Tyra Biosciences, Inc.'s Positivity rank?

Tyra Biosciences, Inc. is ranked #4,427 of 6,774 companies globally and #2,208 of 4,000 in United States on PositoAI, with a Positivity Score of 19,477.

Does Tyra Biosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Tyra Biosciences, Inc..

Where can I read the latest news about Tyra Biosciences, Inc.?

Recent headlines about Tyra Biosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Tyra Biosciences, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Tyra Biosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.